Cardio Diagnostics Holdings, Inc Partners with Ascension Borgess Hospital’s Heart Attack Prevention Clinic on Coronary Artery Disease Study
September 06 2023 - 9:16AM
Business Wire
Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of
artificial intelligence-driven precision cardiovascular medicine
tests, today announced its AI-driven Epi+Gen CHD and PrecisionCHD
tests will be leveraged in a research study led by Dr. Vishal
Gupta, a cardiologist and the head of the Heart Attack Prevention
Clinic at Ascension Borgess.
As the burden of cardiovascular disease grows globally, advanced
coronary artery disease (CAD) detection tools are needed to
proactively identify CAD before events occur. Dr. Gupta’s study
aims to determine which new technologies should be routinely used
to optimize the detection of asymptomatic coronary artery disease.
With this study, Dr. Gupta and his team aim to identify effective
coronary artery disease detection technologies to implement as the
standard of care for patients cared for at the Heart Attack
Prevention Clinic.
Cardio Diagnostics' epigenetic and genetic heart disease tests
will be incorporated into an ongoing multi-year study alongside
other CAD detection methods. An innovative cardiologist for
decades, Dr. Gupta, who has been credited with advancing
personalized cardiovascular medicine, is board-certified in
Internal Medicine, Cardiovascular Disease, and Interventional
Cardiology.
“Early and more precise detection of coronary artery disease
coupled with actionable insights can save lives through preventive
care before heart attacks occur,” said Dr. Gupta. “This research
will help us determine which diagnostic tools offer value in
finding hidden heart disease in asymptomatic patients.”
The costs associated with cardiovascular disease are
substantial. According to the American Heart Association,
cardiovascular disease direct medical costs and indirect costs will
top $1 trillion by 2035 in the United States alone.
Early detection and prevention of cardiovascular disease using
advanced technologies like Cardio Diagnostics' AI-powered tests,
PrecisionCHD and Epi+Gen CHD, may significantly reduce costs.
Preventing just one heart attack avoids around $24,000 in direct
medical costs. By enabling more precise assessments and earlier
interventions, these innovative diagnostic tests may prevent costly
and potentially deadly heart attacks before they happen.
“We are excited to support Dr. Gupta’s groundbreaking research
into optimized coronary artery disease detection,” said Cardio
Diagnostics CEO Meesha Dogan, PhD. “Our AI-powered epigenetic and
genetic cardiovascular tests aim to provide insights that currently
cannot be obtained through existing methods to personalize patient
care at the molecular level. We believe this collaboration will
demonstrate their effectiveness as vital tools for uncovering
asymptomatic heart disease, whether it be obstructive or
non-obstructive, and in helping guide patient care.”
Ascension Borgess is a leading provider of innovative
cardiovascular care and one of the nation’s leading hospitals. This
study exemplifies their commitment to translating research into
solutions and to helping advance best practices to improve patient
outcomes. Cardio Diagnostics is eager to share the results that
could help advance primary and secondary prevention of cardiac
events nationwide through early CAD detection. This partnership
exemplifies our shared goal of advancing precision cardiovascular
medicine.
About Ascension
Ascension is one of the nation’s leading non-profit and Catholic
health systems, with a Mission of delivering compassionate,
personalized care to all, with particular attention to persons
living in poverty and those most vulnerable. In FY2022, Ascension
provided $2.3 billion in care for impoverished persons and other
community benefit programs. Ascension includes approximately
139,000 associates and 36,000 aligned providers and operates more
than 2,600 sites of care – including 139 hospitals in 19
states.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered
precision cardiovascular medicine company that makes cardiovascular
disease prevention, detection, and management more accessible,
personalized, and precise. The Company was formed to further
develop and commercialize clinical tests by leveraging a
proprietary Artificial Intelligence (AI)-driven Integrated
Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular
disease to become one of the leading medical technology companies
for improving prevention, detection, and treatment of
cardiovascular disease. For more information, please visit
www.cardiodiagnosticsinc.com.
Forward-Looking Statements
Certain statements and information included in this press
release constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Act of 1995. When used in this
press release, the words or phrases “will”, "will likely result,"
"expected to," "will continue," "anticipated," "estimate,"
"projected," "intend," “goal,” or similar expressions are intended
to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks, known and unknown, and uncertainties,
many of which are beyond the control of the Company. Such
uncertainties and risks include but are not limited to, our ability
to successfully execute our growth strategy, changes in laws or
regulations, economic conditions, dependence on management,
dilution to stockholders, lack of capital, the effects of rapid
growth upon the Company and the ability of management to
effectively respond to the growth and demand for products and
services of the Company, newly developing technologies, the
Company’s ability to compete, regulatory matters, protection of
technology, the effects of competition and the ability of the
Company to obtain future financing. An extensive list of factors
that can affect future results are discussed in the Current Report
on Form 10-K for the period ended December 31, 2022 and Form 10-Q
for the period ended June 30, 2023 under the heading “Risk Factors”
in Part I, Item IA thereof, and other documents filed from time to
time with the Securities and Exchange Commission. Such factors
could materially adversely affect the Company's financial
performance and could cause the Company's actual results for future
periods to differ materially from any opinions or statements
expressed within this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906590229/en/
Investors: Gene Mannheimer Investor Relations 855-226-9991
investors@cardiodiagnosticsinc.com
Media & Public Relations: Khullani Abdullahi
pr@cardiodiagnosticsinc.com
Cardio Diagnostics (NASDAQ:CDIO)
Historical Stock Chart
From Apr 2024 to May 2024
Cardio Diagnostics (NASDAQ:CDIO)
Historical Stock Chart
From May 2023 to May 2024